Disease · MONDO_0005029

essential thrombocythemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. essential thrombocythemia. Diseases, record MONDO_0005029. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005029

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: essential thrombocythemia; Open Targets
Open Targets ID: MONDO_0005029; Open Targets
Other names: essential thrombocytemia, essential thrombocythaemia, essential thrombocytosis, hemorrhagic thrombocythemia, primary thrombocythemia, primary thrombocytosis; Open Targets
Disease Ontology: DOID:2224; Disease Ontology
MeSH: D013920; MeSH
NCI Thesaurus: C3407; NCI Thesaurus
Orphanet: ORPHA:3318; Orphanet
Highest stage of its drugs: Approval, for 5 of its 32 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs32

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ANAGRELIDE	CHEMBL760	Small molecule	Approval	EMA Human Drugs	12	9	9	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Approval	TTD	8	6	6	Drugs and targets
ANAGRELIDE HYDROCHLORIDE	CHEMBL1200759	Small molecule	Approval	DailyMed	8	4	4	Drugs and targets
PEGINTERFERON ALFA-2A	CHEMBL1201560	Protein	Approval	EMA Human Drugs	3	2	0	Drugs and targets
MOMELOTINIB DIHYDROCHLORIDE	CHEMBL2219411	Small molecule	Approval	FDA	1	0	0	Drugs and targets
ROPEGINTERFERON ALFA-2B	CHEMBL4297819	Protein	Phase 3	ClinicalTrials.gov and TTD	7	6	4	Drugs and targets
BOMEDEMSTAT	CHEMBL4297289	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
HYDROXYUREA	CHEMBL467	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
INTERFERON ALFA-2A	CHEMBL2108508	Protein	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 3	ClinicalTrials.gov	5	5	2	Drugs and targets

1 to 10 of 32

See all 32 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK2	Tyrosine-protein kinase JAK2	6	Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3455	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	3	Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	2	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets
HDAC1	Histone deacetylase	2	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	2	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	2	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	2	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets
MDM2	Tumour suppressor p53/oncoprotein Mdm2	2	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/4193	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials50

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01259856	Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)	Phase 3	168	2018-07-24	High Risk Polycythemia Vera, High Risk Essential Thrombocythemia	HYDROXYUREA, INTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov
NCT02124746	Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia	Phase 2	87	2021-02-05	Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia	MOMELOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00452023	Pegasys® in Patients With Myeloproliferative Diseases	Phase 2	83	2024-12-11	Myeloproliferative Disorders	INTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov
NCT00669578	CC-4047 in Treating Patients With Myelofibrosis	Phase 1/2	77	2014-05-09	Chronic Myeloproliferative Disorders, Secondary Myelofibrosis	POMALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00726232	Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia	Phase 2	73	2012-02-24	Myeloproliferative Neoplasm (MPN)	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT04254978	Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)	Phase 2	73	2024-04-02	Essential Thrombocythemia	BOMEDEMSTAT	Its record names the disease	ClinicalTrials.gov
NCT01214915	Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia	Phase 3	53	2013-09-25	Essential Thrombocythemia (ET)	ANAGRELIDE, ANAGRELIDE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01352585	Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®		47	2014-07-29	Essential Thrombocythemia (ET)	ANAGRELIDE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01467661	Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia	Phase 3	41	2016-06-08	Essential Thrombocythemia (ET)	ANAGRELIDE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00606307	Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases	Phase 2	29	2019-12-03	Myeloproliferative Diseases	GIVINOSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 50

See all 50 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PEGASYS vs Hydroxyurea: Number of Participants With Major Cardiovascular Events After Therapy	1 of 82	1 of 86	168	NCT01259856	Trial comparisons
PEGASYS vs Hydroxyurea: deaths from any cause	0 of 82	1 of 86	168	NCT01259856	Trial comparisons
PEGASYS vs Hydroxyurea: serious adverse events	14 of 82	4 of 86	168	NCT01259856	Trial comparisons
SPD422: Safety Analysis Set vs SPD422: Post-marketing Trial Safety Analysis Set: serious adverse events	21 of 53	1 of 33	86	NCT01467661	Trial comparisons
JAK2 Positive Participants vs JAK2 Negative Participants: serious adverse events	0 of 23	0 of 24	47	NCT01352585	Trial comparisons
JAK2 Positive Participants vs JAK2 Negative Participants: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months	12 of 14	14 of 21	35	NCT01352585	Trial comparisons
JAK2 Positive Participants vs JAK2 Negative Participants: Number of Patients With Platelet Count ≤400x10^9/L After 12 Months	7 of 14	8 of 21	35	NCT01352585	Trial comparisons
Agrylin (Young) vs Agrylin (Elderly): serious adverse events	0 of 12	0 of 12	24	NCT00413634	Trial comparisons
Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib Placebo: deaths from any cause	0 of 5	0 of 6	11	NCT03123588	Trial comparisons
Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib PLacebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs)	5 of 5	4 of 6	11	NCT03123588	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials30

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41758981	RESULT	1	PubMed
30409796	RESULT	1	PubMed
30121892	RESULT	1	PubMed
26028965	RESULT	1	PubMed
25160063	RESULT	1	PubMed
42751490	DERIVED	1	PubMed
42588744	DERIVED	1	PubMed
42306077	DERIVED	1	PubMed
41193116	DERIVED	1	PubMed
40775758	DERIVED	2	PubMed

1 to 10 of 30

See all 30 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005029

GET https://conductscience.org/api/diseases/v1/MONDO_0005029/drugs?page=2

API reference For AI assistants